Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>: Implications for Dose Optimization.

Overview

The present study evaluated the in vitro potency of ceftazidime and cefepime amongst carbapenem-resistant Pseudomonas aeruginosa collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.